Abivax 2021 Financial Communication Calendar
PARIS, FRANCE, December 3, 2020 – 6:00 p.m. (CET) – Abivax (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today publishes its 2021 financial communication calendar.
Thursday, April 1, 2021
Publication of financial statements as of December 31, 2020
Friday, April 30, 2021
Publication and release of the 2020 annual financial report
Friday, June 4, 2021 – 10.00 a.m.
Shareholders meeting
Thursday, September 23, 2021
Publication of financial statements as of June 30, 2021
Thursday, September 30, 2021
Publication and release of 2021 half year report
About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment C (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.
Contacts
| Abivax Communications Regina Jehle regina.jehle@abivax.com +33 6 24 50 69 63 |
Investors LifeSci Advisors Chris Maggos chris@lifesciadvisors.com +41 79 367 6254 |
Press Relations & Investors Europe MC Services AG Anne Hennecke anne.hennecke@mc-services.eu +49 211 529 252 22 |
| Public Relations France Actifin Ghislaine Gasparetto ggasparetto@actifin.fr +33 6 21 10 49 24 |
Public Relations France DGM Conseil Thomas Roborel de Climens thomasdeclimens@dgm-conseil.fr +33 6 14 50 15 84 |
Public Relations USA Rooney Partners LLC Marion Janic mjanic@rooneyco.com +1 212 223 4017 |